[Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism].
OBJECTIVE
The gene polymorphism is used to predict the sensitivity of chemotherapy, which is significant for the individualized treatment of tumor. This study was to explore the correlation of codon 194 and codon 399 polymorphisms of DNA repair gene X-ray repair cross complementing (XRCC1) with the sensitivity of non-small cell lung cancer (NSCLC) to NP (vinorebine and cisplatin) chemotherapy.


METHODS
XRCC1 polymorphisms at codon 194 and codon 399 were detected in 164 patients with NSCLC using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The haplotype of XRCC1 gene was analyzed using SHEsis analysis software. Patients treated with NP chemotherapy were evaluated after two periods of treatment, then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed.


RESULTS
The patients with the XRCC1 codon 194 C/T+T/T polymorphisms were 2.038 times as sensitive to the chemotherapy as the patients with C/C genotype (P=0.036, 95% CI:1.044-3.976). The effective rate to chemotherapy was no significant difference between the patients with XRCC1 codon 399 G/G, A/G, and A/A polymorhism. The effective rate of chemotherapy of the patients with T-A haplotype significantly increased compared with those with other haplotype (P=0.031), while that of the patients with C-A haplotype significantly decreased compared with others(P=0.035).


CONCLUSIONS
The sensitivity to NP chemotherapy significantly increased in the NSCLC patients with XRCC1 194 CT and TT genotypes compared with those with CC genotype. XRCC1 codon 194 and codon 399 polymorphisms may be used to predict the sensitivity of NSCLC to NP chemotherapy.
Hong
Cheng-Yu
CY
Cancer Control Laboratory of Cancer Institute and General Surgery Institute, The First Affiliated Hospital of China Medical University,The Key Laboratory of Cancer Control of Liaoning Province, Shenyang, Liaoning, 110001,P. R. China.
Xu
Qian
Q
Yue
Zheng
Z
Zhang
Ye
Y
Yuan
Yuan
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage; D003062:Codon; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006239:Haplotypes; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012074:Remission Induction; D012680:Sensitivity and Specificity; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000076105:X-ray Repair Cross Complementing Protein 1
D003062:Codon; D004268:DNA-Binding Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine